Showing results (821-830 of 2,947) with videos related to

Sort By:
Pageof 295
Molecular and Clinical Oncology|January 27, 2017
Lipomatous angiomyofibroblastoma of the vulva: A case report and review of the literatureSusumu Matsukuma, Ayano Koga, Ryohei Suematsu, et al.
Molecular and Clinical Oncology|January 27, 2017
Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysisHajime Yonezawa, Hirofumi Hirano, Hiroyuki Uchida, et al.
Molecular and Clinical Oncology|January 27, 2017
Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancerKazuhiko Sakamoto, Shigeru Takeda, Shinsuke Kanekiyo, et al.
Molecular and Clinical Oncology|July 26, 2019
Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysisKazuyuki Numakura, Yohei Horikawa, Sachiko Kamada, et al.
Molecular and Clinical Oncology|July 19, 2019
Resection of anterior mediastinal ectopic pancreas by right thoracoscopy: A case reportHonglin Zhao, Zihe Zhang, Xin Li, et al.
Molecular and Clinical Oncology|March 9, 2019
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trialsZeina Nahleh, Gehan Botrus, Alok Dwivedi, et al.
Molecular and Clinical Oncology|March 9, 2019
Expression of keratin 15 in dentigerous cyst, odontogenic keratocyst and ameloblastomaMohammed Amjed Alsaegh, Alaa Muayad Altaie, Shengrong Zhu
Molecular and Clinical Oncology|March 9, 2019
Short term outcomes of helical tomotherapy during concurrent chemoradiotherapy for advanced cervical cancerYasushi Mabuchi, Yoshihiro Takiguchi, Tamaki Yahata, et al.
Molecular and Clinical Oncology|March 9, 2019
Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case reportThéophraste Henry, Elizabeth Fabre, Laurent S Baccar, et al.
Molecular and Clinical Oncology|February 19, 2021
The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancerYoichiro Tohi, Iori Matsuda, Kengo Fujiwara, et al.
Pageof 295